title: Rebamipide enema therapy for left-sided ischemic colitis patients accompanied by ulcers: open label study.
abstract: OBJECTIVE
  To attempt rectal administration of rebamipide in the treatment of ischemic colitis patients with ulcers, and evaluate its effects.
  
  
  METHODS
  We compared 9 ischemic colitis patients (2 men, 7 women) with ulcers treated by bowel rest only from 2000 to 2005 (conventional therapy group), with 6 patients (2 men, 4 women) treated by rebamipide enema therapy in 2006 (rebamipide enema therapy group) and analyzed the mean duration of fasting and hospitalization, degree of ulcer healing, and decrease in WBC count for the two groups.
  
  
  RESULTS
  The mean duration of fasting and hospitalization were 2.7+/-1.8 d and 9.2+/-1.5 d in the rebamipide group and 7.9+/-4.1 d and 17.9+/-6.8 d in the control group, respectively, and significantly reduced in the rebamipide group (t= -2.915; P=0.0121 and t= -3.054; P=0.0092). As for the degree of ulcer healing at 7 d after admission, the ulcer score was reduced by 3.5+/-0.5 (points) in the rebamipide group and 2.8+/-0.5 (points) in the control group (t=1.975; P=0.0797), while the decrease in WBC count was 120.0+/-55.8 (x 10(2)/microL) in the rebamipide group and 85.9+/-56.8 (x 10(2)/microL) in the control group (t=1.006; P=0.3360).
  
  
  CONCLUSIONS
  In left-sided ischemic colitis patients with ulcers, rebamipide enema therapy significantly reduced the duration of fasting and hospitalization, recommending its use as a new and effective therapeutic alternative.
authors.affiliation: Department of Internal Medicine, Kamigoto Hospital, 1549-11 Aokata-gou, Shinkamigoto-cho, Minamimatsuura-gun, Nagasaki 857-4404, Japan. hiyo-mana@gol.com
authors.forename: Satohiro
authors.initials: S
authors.lastname: Matsumoto
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Tsuji
authors.forename: Satoshi
authors.initials: S
authors.lastname: Shirahama
mesh_terms: D000285:Administration, Rectal; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017091:Colitis, Ischemic / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D003093:Colitis, Ulcerative / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D003106:Colon / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D003113:Colonoscopy; D004733:Enema; D005215:Fasting; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D007902:Length of Stay; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D015363:Quinolones / Q000008:administration & dosage*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
chemical_list: D005765:Gastrointestinal Agents; D015363:Quinolones; C052785:rebamipide; D000409:Alanine